{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:42:34Z","timestamp":1768250554573,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1R01AI091422 and 1R01AI097142"],"award-info":[{"award-number":["1R01AI091422 and 1R01AI097142"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fungal Genetics and Biology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.fgb.2014.12.001","type":"journal-article","created":{"date-parts":[[2014,12,13]],"date-time":"2014-12-13T07:15:56Z","timestamp":1418454956000},"page":"93-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Toward improved anti-cryptococcal drugs: Novel molecules and repurposed drugs"],"prefix":"10.1016","volume":"78","author":[{"given":"Damian J.","family":"Krysan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.fgb.2014.12.001_b0005","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/jac\/dkr500","article-title":"Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin, and thioridazine","volume":"67","author":"Abbate","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.fgb.2014.12.001_b0010","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1128\/AAC.00477-12","article-title":"Amino acid-derived 1,2-benisothiazolinone derivatives as novel small-molecule antifungal inhibitors: identification of potential genetic targets","volume":"56","author":"Alex","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.fgb.2014.12.001_b0015","doi-asserted-by":"crossref","first-page":"e7124","DOI":"10.1371\/journal.pone.0007124","article-title":"Screen for specific modulators of autophagy reveals novel therapeutic inhibitors of TORC1 signaling","volume":"4","author":"Balgi","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.fgb.2014.12.001_b0020","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/604716","article-title":"Independent association of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of combined cohort of 262 patients","volume":"49","author":"Bicanic","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.fgb.2014.12.001_b0025","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2174\/156802612804547344","article-title":"Drug repurposing in chemical genomics: can we learn from the past to improve the future?","volume":"12","author":"Bisson","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.fgb.2014.12.001_b0040","doi-asserted-by":"crossref","first-page":"e1002870","DOI":"10.1371\/journal.ppat.1002870","article-title":"Antifungal drug discovery: something old and something new","volume":"8","author":"Butts","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.fgb.2014.12.001_b0030","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1128\/EC.00314-12","article-title":"A re-purposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis","volume":"12","author":"Butts","year":"2013","journal-title":"Eukaryot. Cell"},{"key":"10.1016\/j.fgb.2014.12.001_b0035","doi-asserted-by":"crossref","first-page":"e00765","DOI":"10.1128\/mBio.00765-13","article-title":"Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF-hand proteins and synergize with fluconazole in vivo","volume":"5","author":"Butts","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.fgb.2014.12.001_b0045","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.idc.2006.07.001","article-title":"Cryptococcosis","volume":"20","author":"Chayakulkeeree","year":"2006","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"10.1016\/j.fgb.2014.12.001_b0050","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nchembio806","article-title":"A clinical drug library screen identifies astemizole as an antimalarial agent","volume":"2","author":"Chong","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.fgb.2014.12.001_b0055","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMoa1110404","article-title":"Combination therapy for cryptococcal meningitis","volume":"368","author":"Day","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.fgb.2014.12.001_b0060","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/nprot.2010.47","article-title":"A high-throughput assay of yeast cell lysis for drug discovery and genetic analysis","volume":"5","author":"DiDone","year":"2010","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.fgb.2014.12.001_b0065","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1016\/j.bmc.2011.08.029","article-title":"Antifungal activity of a series of 1,2-benzisothiazol-3(2H)-one derivatives","volume":"19","author":"Dou","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.fgb.2014.12.001_b0070","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1093\/bioinformatics\/bti1124","article-title":"Lineage-specific gene loss following mitochondrial endosymbiosis and its potential for function prediction in eukaryotes","volume":"21","author":"Gabaldon","year":"2005","journal-title":"Bioinformatics"},{"key":"10.1016\/j.fgb.2014.12.001_b0075","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1128\/AAC.01728-09","article-title":"Mechanism of synergistic effect of amiodarone and fluconazole in C. albicans","volume":"54","author":"Gamarra","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.fgb.2014.12.001_b0080","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1128\/AAC.00366-11","article-title":"Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis and fusariosis","volume":"55","author":"Hata","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.fgb.2014.12.001_b0085","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/bjc.1991.147","article-title":"Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients","volume":"63","author":"Lein","year":"1991","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.fgb.2014.12.001_b0090","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.01159-07","article-title":"In vitro and in vivo antifungal activities of T-2307, a novel arylamidine","volume":"52","author":"Mitsuyama","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.fgb.2014.12.001_b0095","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1128\/AAC.47.3.917-922.2003","article-title":"Clinical concentrations of thioridazine kill intracellular multi-drug resistant Mycobacterium tuberculosis","volume":"47","author":"Ordway","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.fgb.2014.12.001_b0100","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/QAD.0b013e328322ffac","article-title":"Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS","volume":"23","author":"Park","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.fgb.2014.12.001_b0105","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1056\/NEJMe1302038","article-title":"Efficiently killing a sugar-coated yeast","volume":"368","author":"Perfect","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.fgb.2014.12.001_b0110","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.fgb.2014.12.001_b0115","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1016\/j.bmcl.2013.06.096","article-title":"Synthesis and antifungal activities of miltefosine analogs","volume":"23","author":"Ravu","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.fgb.2014.12.001_b0120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0090-9556(25)07102-8","article-title":"Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient","volume":"19","author":"Robinson","year":"1991","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.fgb.2014.12.001_b0125","first-page":"4","article-title":"Antifungal drug development: challenges, unmet clinical needs, and new approaches","volume":"1","author":"Roemer","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.fgb.2014.12.001_b0130","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/cid\/cit342","article-title":"Cryptococcosis due to Cryptococcus gattii","volume":"57","author":"Rolston","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.fgb.2014.12.001_b0135","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1128\/AAC.05954-11","article-title":"T-2307 causes collapse of mitochondrial membrane potential in yeast","volume":"56","author":"Shibata","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.fgb.2014.12.001_b0140","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/QCO.0b013e32832fa214","article-title":"Treatment of cryptococcal meningitis in resource-limited settings","volume":"22","author":"Sloan","year":"2009","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.fgb.2014.12.001_b0145","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/msb.2011.31","article-title":"Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole","volume":"7","author":"Spitzer","year":"2011","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.fgb.2014.12.001_b0150","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nrmicro1680","article-title":"Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections","volume":"5","author":"Steinbach","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.fgb.2014.12.001_b0155","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nm.3595","article-title":"Overcoming drug development bottlenecks with repurposing","volume":"20","author":"Strittmatter","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.fgb.2014.12.001_b0160","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1046\/j.1365-2958.2003.03481.x","article-title":"Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly","volume":"48","author":"Tsukahara","year":"2003","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.fgb.2014.12.001_b0165","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/13693780903081968","article-title":"Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii","volume":"48","author":"Vu","year":"2010","journal-title":"Med. Mycol."},{"key":"10.1016\/j.fgb.2014.12.001_b0170","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1021\/jm030480f","article-title":"Selective optimization of side activities: another way for drug discovery","volume":"47","author":"Wermuth","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.fgb.2014.12.001_b0175","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/AAC.50.2.414-421.2006","article-title":"Hexadecylphophocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis","volume":"50","author":"Widmer","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.fgb.2014.12.001_b0180","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1128\/AAC.01624-12","article-title":"Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis","volume":"57","author":"Wiederhold","year":"2013","journal-title":"Antimicrob. Agents Chemoether."},{"key":"10.1016\/j.fgb.2014.12.001_b0185","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ijantimicag.2012.11.006","article-title":"Evaluation of the anticryptococcal activity of antibiotic polymixin B in vitro and in vivo","volume":"41","author":"Zhai","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.fgb.2014.12.001_b0195","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/jac\/dkq046","article-title":"Polymixin B, in combination with fluconazole, exerts a potent fungicidal effect","volume":"65","author":"Zhai","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.fgb.2014.12.001_b0190","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1128\/AAC.00212-12","article-title":"The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections","volume":"56","author":"Zhai","year":"2012","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Fungal Genetics and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1087184514002163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1087184514002163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:40:49Z","timestamp":1747186849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1087184514002163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":39,"alternative-id":["S1087184514002163"],"URL":"https:\/\/doi.org\/10.1016\/j.fgb.2014.12.001","relation":{},"ISSN":["1087-1845"],"issn-type":[{"value":"1087-1845","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toward improved anti-cryptococcal drugs: Novel molecules and repurposed drugs","name":"articletitle","label":"Article Title"},{"value":"Fungal Genetics and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fgb.2014.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}